Solu Therapeutics

Solu Therapeutics company information, Employees & Contact Information

Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases.

Company Details

Employees
23
Address
Boston , Ma, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston , MA
Looking for a particular Solu Therapeutics employee's phone or email?

Solu Therapeutics Questions

News

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies - PR Newswire

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies PR Newswire

Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer - PR Newswire

Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer PR Newswire

Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer - MedCity News

Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer MedCity News

Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer - Business Wire

Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer Business Wire

Boston biotech Solu raises $41M Series A - Axios

Boston biotech Solu raises $41M Series A Axios

Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets - Genetic Engineering and Biotechnology News

Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets Genetic Engineering and Biotechnology News

Solu Therapeutics Closes $41M Series A Financing - FinSMEs

Solu Therapeutics Closes $41M Series A Financing FinSMEs

Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets - Business Wire

Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets Business Wire

Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting - PR Newswire

Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting PR Newswire

Top Solu Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant